* \<18 years of age * patient is known to be pregnant * known active malignancy that required treatment in the last year * who class iii or iv pulmonary hypertension * venous thromboembolism currently receiving anti-coagulation or within the past 3 months * currently receiving extracorporeal life support * severe chronic liver disease (child-pugh score \>12) * "do not attempt resuscitation" order in place * treatment withdrawal imminent within 24 hours * bmi \> 45 kg/m2. * received any investigational research agent within 60 days or within five half-lives of the last treatment (if the half-life of the investigational agent is known to be longer than 12 days) prior to the planned administration of study treatment. * known positive test for human immunodeficiency virus 1 (hiv 1), hiv 2, hepatitis b virus, hepatitis c virus or any other infection which the opinion of the investigator is likely to impact on the ability of the patient to participate in the study. * known sensitivity to dimethylsulfoxide (dmso) or any other component of the study treatment.

* \<18 years of age * patient is known to be pregnant * known active malignancy that required treatment in the last year * who class iii or iv pulmonary hypertension * venous thromboembolism currently receiving anti-coagulation or within the past 3 months * currently receiving extracorporeal life support * severe chronic liver disease (child-pugh score \>12) * "do not attempt resuscitation" order in place * treatment withdrawal imminent within 24 hours * bmi \> 45 kg/m2. * received any investigational research agent within 60 days or within five half-lives of the last treatment (if the half-life of the investigational agent is known to be longer than 12 days) prior to the planned administration of study treatment. * known positive test for human immunodeficiency virus 1 (hiv 1), hiv 2, hepatitis b virus, hepatitis c virus or any other infection which the opinion of the investigator is likely to impact on the ability of the patient to participate in the study. * known sensitivity to dimethylsulfoxide (dmso) or any other component of the study treatment.

- <18 years of age - patient is known to be pregnant - known active malignancy that required treatment in the last year - who class iii or iv pulmonary hypertension - venous thromboembolism currently receiving anti-coagulation or within the past 3 months - currently receiving extracorporeal life support - severe chronic liver disease (child-pugh score >12) - "do not attempt resuscitation" order in place - treatment withdrawal imminent within 24 hours - bmi > 45 kg/m2. - received any investigational research agent within 60 days or within five half-lives of the last treatment (if the half-life of the investigational agent is known to be longer than 12 days) prior to the planned administration of study treatment. - known positive test for human immunodeficiency virus 1 (hiv 1), hiv 2, hepatitis b virus, hepatitis c virus or any other infection which the opinion of the investigator is likely to impact on the ability of the patient to participate in the study. - known sensitivity to dimethylsulfoxide (dmso) or any other component of the study treatment.

- <18 years of age - patient is known to be pregnant - known active malignancy that required treatment in the last year - who class iii or iv pulmonary hypertension - venous thromboembolism currently receiving anti-coagulation or within the past 3 months - currently receiving extracorporeal life support - severe chronic liver disease (child-pugh score >12) - "do not attempt resuscitation" order in place - treatment withdrawal imminent within 24 hours - bmi > 45 kg/m2. - received any investigational research agent within 60 days or within five half-lives of the last treatment (if the half-life of the investigational agent is known to be longer than 12 days) prior to the planned administration of study treatment. - known positive test for human immunodeficiency virus 1 (hiv 1), hiv 2, hepatitis b virus, hepatitis c virus or any other infection which the opinion of the investigator is likely to impact on the ability of the patient to participate in the study. - known sensitivity to dimethylsulfoxide (dmso) or any other component of the study treatment.